• Jisoo Baek, Jinmi Kim, Seonmi Shin, and Chungsik Cho.
• Department of Internal Korean Medicine, College of Korean Medicine, Dae-Jeon University, Daejeon, Republic of Korea,Department. of Internal Korean Medicine, College of Korean Medicine, Se-Myung University, Chungcheongbukdo, South Korea.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundThis systematic review and meta-analysis of randomized controlled trials (RCTs) will aim to assess the efficacy and safety of Yukmijihwang-hwan for type 2 diabetes without complications.MethodsTo identify eligible studies, we will perform a systematic search of the following electronic databases: MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Citation Information by NII, Korean Information Service System, Korean Medical Database, Oriental Medicine Advanced Searching Integrated System, and ScienceON. Search terms will include "Type 2 Diabetes" for participants as well as "Yukmijihwang-tang" or "Liuwei dihuang tang" for interventions. Two independent researchers will perform data extraction and assessment using Cochrane's risk of bias tool, with disagreements being resolved through discussions with a third researcher.ResultsThis study will evaluate the antidiabetic effects of Yukmijihwang-hwan from 3 perspectives (blood glucose level, insulin resistance, and β-cell function) as well as its safety by reviewing the reported adverse effects.ConclusionThis systematic review will provide evidence regarding the antidiabetic efficacy and safety of Yukmijihwang-tang in type 2 diabetes mellitus.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…